Stasi R - Search Results

1

ITP: a historical perspective.

Stasi R, Newland AC. Stasi R, et al. Br J Haematol. 2011 May;153(4):437-50. doi: 10.1111/j.1365-2141.2010.08562.x. Epub 2011 Apr 5. Br J Haematol. 2011. PMID: 21466538

2

Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.

Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB. Cooper N, et al. Among authors: stasi r. Br J Haematol. 2012 Aug;158(4):539-47. doi: 10.1111/j.1365-2141.2012.09184.x. Epub 2012 Jul 6. Br J Haematol. 2012. PMID: 22775462

3

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).

Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, Chiarini F, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M. Amadori S, et al. Among authors: stasi r. Br J Haematol. 2012 Jan;156(2):205-12. doi: 10.1111/j.1365-2141.2011.08940.x. Epub 2011 Nov 15. Br J Haematol. 2012. PMID: 22082314 Clinical Trial.

4

The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.

Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, Ottone T, Del Principe MI, Buccisano F, Maurillo L, Panetta P, de Fabritiis P, Stasi R, Venditti A, Amadori S, Lo Coco F. Del Poeta G, et al. Among authors: stasi r. Br J Haematol. 2010 May;149(3):383-7. doi: 10.1111/j.1365-2141.2010.08098.x. Epub 2010 Feb 8. Br J Haematol. 2010. PMID: 20148885

5

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.

Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S. Stasi R, et al. Br J Haematol. 1994 Dec;88(4):770-7. doi: 10.1111/j.1365-2141.1994.tb05116.x. Br J Haematol. 1994. PMID: 7819101 Clinical Trial.

6

Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.

Stasi R. Stasi R. Expert Rev Hematol. 2008 Dec;1(2):145-52. doi: 10.1586/17474086.1.2.145. Expert Rev Hematol. 2008. PMID: 21082919 Review.

7

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review.

Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Stasi R, et al. Blood. 2009 Feb 5;113(6):1231-40. doi: 10.1182/blood-2008-07-167155. Epub 2008 Oct 22. Blood. 2009. PMID: 18945961 Review.

8

Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia.

Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Stasi R, et al. PLoS Med. 2006 Mar;3(3):e24. doi: 10.1371/journal.pmed.0030024. PLoS Med. 2006. PMID: 16401142 Free PMC article.

9

Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura.

Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Stasi R, et al. Am J Med. 2005 Apr;118(4):414-9. doi: 10.1016/j.amjmed.2004.09.014. Am J Med. 2005. PMID: 15808140

10

Management of immune thrombocytopenic purpura in adults.

Stasi R, Provan D. Stasi R, et al. Mayo Clin Proc. 2004 Apr;79(4):504-22. doi: 10.4065/79.4.504. Mayo Clin Proc. 2004. PMID: 15065616 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results